Selected publications
- Perspectives in melanoma: Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). Journal of Translational Medicine. 2019 Conference Paper GET IT
-
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
The Lancet Oncology.
2019
Review
GET IT
Times cited: 2 -
Adverse events 2.0—Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.
European Journal of Cancer.
2019
Information Resource
GET IT
Times cited: 2 -
Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results.
Journal of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 6 -
CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer.
Journal of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 57 -
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).
Journal of Translational Medicine.
2018
Academic Article
GET IT
Times cited: 1 -
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Cancer Cell.
2018
Academic Article
GET IT
Times cited: 168 -
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
Journal of Translational Medicine.
2017
Academic Article
GET IT
Times cited: 8 -
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.
Journal of Translational Medicine.
2017
Editorial Article
GET IT
Times cited: 10 -
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
European Journal of Cancer.
2017
Review
GET IT
Times cited: 105 -
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody.
Clinical Cancer Research.
2017
Academic Article
GET IT
Times cited: 67 -
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
The Lancet Oncology.
2017
Academic Article
GET IT
Times cited: 33 -
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.
European Journal of Cancer.
2017
Academic Article
GET IT
Times cited: 16 -
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab.
Clinical Cancer Research.
2016
Academic Article
GET IT
Times cited: 180 -
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Journal of Translational Medicine.
2016
Article
GET IT
Times cited: 11 - Perspectives in immunotherapy: Meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. Journal for ImmunoTherapy of Cancer. 2016 Academic Article GET IT
-
Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab.
Clinical Cancer Research.
2016
Academic Article
GET IT
Times cited: 59 -
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.
European Journal of Cancer.
2016
Academic Article
GET IT
Times cited: 21 -
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab.
Clinical Cancer Research.
2016
Academic Article
GET IT
Times cited: 186 -
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial.
The Lancet Oncology.
2015
Academic Article
GET IT
Times cited: 543 -
Expanded access programmes: Patient interests versus clinical trial integrity.
The Lancet Oncology.
2015
Comment
GET IT
Times cited: 5 -
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial.
The Lancet Oncology.
2015
Academic Article
GET IT
Times cited: 774 -
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study.
The Lancet Oncology.
2014
Academic Article
GET IT
Times cited: 582 -
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
Journal of Pathology.
2014
Review
GET IT
Times cited: 542 -
Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases.
Expert Review of Dermatology.
2013
Report
GET IT
Times cited: 3 -
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial.
The Lancet Oncology.
2012
Academic Article
GET IT
Times cited: 572